검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AIN457 |
Overview Company | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Relapsing-remitting Multiple Sclerosis |
Overview Indication | Uveitis |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | targeting IL-17 and its receptor |
MoA Biomarker | biomarkers (e |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.. While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities. In the recent past, there has been increasing evidence that interleukin (IL)-17 plays a vital role in the pathophy… |
Clinical Primary efficacy | ORR 9% |
Clinical ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT01090310 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AIN457 |
Overview Company | Novartis Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Relapsing-remitting Multiple Sclerosis |
Overview Indication | Uveitis |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | targeting IL-17 and its receptor |
MoA Biomarker | biomarkers (e |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.. While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities. In the recent past, there has been increasing evidence that interleukin (IL)-17 plays a vital role in the pathophy… |
Clinical Primary efficacy | ORR 9% |
Clinical ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT01090310 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교